scispace - formally typeset
V

Vincent Meininger

Researcher at Aventis Pharma

Publications -  180
Citations -  16470

Vincent Meininger is an academic researcher from Aventis Pharma. The author has contributed to research in topics: Amyotrophic lateral sclerosis & Riluzole. The author has an hindex of 57, co-authored 175 publications receiving 14803 citations. Previous affiliations of Vincent Meininger include University of Cambridge.

Papers
More filters
Journal ArticleDOI

Diffusion tensor imaging and voxel based morphometry study in amyotrophic lateral sclerosis: relationships with motor disability

TL;DR: Results show that subcortical lesions extend beyond the corticospinal tract and are clinically relevant in ALS patients, and voxel based morphometry showed no changes in white matter but widespread volume decreases in grey matter in several regions exhibiting MD abnormalities.
Journal ArticleDOI

Progression in ALS is not linear but is curvilinear

TL;DR: The aim of the study is to determine the shape of the progression curve in ALS, assess the impact of clinical variables on the rate of progression, and evaluate the association between functional decline and survival.
Journal ArticleDOI

Up-regulation of mitochondrial uncoupling protein 3 reveals an early muscular metabolic defect in amyotrophic lateral sclerosis

TL;DR: It is proposed that UCP3 up‐regulation in skeletal muscle contributes to the characteristic mitochondrial damage of ALS and to the onset of the disease.
Journal ArticleDOI

Three families with amyotrophic lateral sclerosis and frontotemporal dementia with evidence of linkage to chromosome 9p.

TL;DR: The identification of new families enables reduction of the ALS-FTD candidate region located on chromosomes 9p, and the clinical features observed in these families help characterize the profiles of ALS and FTD with linkage to chromosome 9p-linked families.
Journal ArticleDOI

The Kynurenine Pathway and Inflammation in Amyotrophic Lateral Sclerosis

TL;DR: The presence of neuroinflammation in ALS is shown and data point to an inflammation-driven excitotoxic-chelation defective mechanism in ALS, which may be amenable to inhibitors of the KP.